Viktor Grünwald1, Daniel Kalanovic, Axel S Merseburger. 1. Clinic for Hematology, Hemostaseology, Oncology and Stem Cell Transplantation, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625, Hannover, Germany.
Abstract
BACKGROUND: The advance of medical treatment in renal cell carcinoma (RCC) has fostered the development of diverse continuous oral therapies with tyrosine kinase inhibitors (TKI), among these sunitinib remains the mainstay of therapy for most of the patients. Based on its clinical activity, disease control over a period of 11 months can be expected with sunitinib treatment. Given this prolonged period of exposure to sunitinib, adverse events tend to reoccur and can possibly decrease the quality of life in our patients. Hence, development of modalities to detect, treat and cope with such adverse events has become a major focus for physicians and patients. Today, numerous publications address these questions and offer advice from experienced centers. However, these reviews summarize single or oligo-center experiences. METHODS AND RESULTS: Our approach is based (1) on an extensive review and analysis of available evidence from literature and (2) a structured consensus survey among 12 German experts in the field who treated at least 30 patients each with a TKI. CONCLUSIONS: Derived from this process, this paper gives an overview on Sunitinib therapy management recommendations deducted from published evidence and consensus agreement among experts.
BACKGROUND: The advance of medical treatment in renal cell carcinoma (RCC) has fostered the development of diverse continuous oral therapies with tyrosine kinase inhibitors (TKI), among these sunitinib remains the mainstay of therapy for most of the patients. Based on its clinical activity, disease control over a period of 11 months can be expected with sunitinib treatment. Given this prolonged period of exposure to sunitinib, adverse events tend to reoccur and can possibly decrease the quality of life in our patients. Hence, development of modalities to detect, treat and cope with such adverse events has become a major focus for physicians and patients. Today, numerous publications address these questions and offer advice from experienced centers. However, these reviews summarize single or oligo-center experiences. METHODS AND RESULTS: Our approach is based (1) on an extensive review and analysis of available evidence from literature and (2) a structured consensus survey among 12 German experts in the field who treated at least 30 patients each with a TKI. CONCLUSIONS: Derived from this process, this paper gives an overview on Sunitinib therapy management recommendations deducted from published evidence and consensus agreement among experts.
Authors: Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Roberto Pili; Georg A Bjarnason; Xavier Garcia-del-Muro; Jeffrey A Sosman; Ewa Solska; George Wilding; John A Thompson; Sindy T Kim; Isan Chen; Xin Huang; Robert A Figlin Journal: J Clin Oncol Date: 2009-06-01 Impact factor: 44.544
Authors: Manuela Schmidinger; Christoph C Zielinski; Ursula M Vogl; Andja Bojic; Marija Bojic; Christoph Schukro; Marquerite Ruhsam; Michael Hejna; Herwig Schmidinger Journal: J Clin Oncol Date: 2008-10-06 Impact factor: 44.544
Authors: H Izzedine; S Ederhy; F Goldwasser; J C Soria; G Milano; A Cohen; D Khayat; J P Spano Journal: Ann Oncol Date: 2009-01-15 Impact factor: 32.976
Authors: Krishnendu Pal; Ying Cao; Irina N Gaisina; Santanu Bhattacharya; Shamit K Dutta; Enfeng Wang; Hendra Gunosewoyo; Alan P Kozikowski; Daniel D Billadeau; Debabrata Mukhopadhyay Journal: Mol Cancer Ther Date: 2013-12-10 Impact factor: 6.261